Clinical trial
A Multicenter, Randomized, Open Label, Parallel-group Phase IIB Study on the Efficacy and Safety of Oral Regimens of DEB025 Alone or in Combination With Ribavirin Versus Standard of Care (Peg-IFNα2a Plus Ribavirin) in Treatment-naïve Hepatitis C Genotype 2 and 3 Patients
NCT01215643 is registered in ClinicalTrials.gov with Debiopharm International SA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Open Label, Parallel-group Phase IIB Study on the Efficacy and Safety of Oral Regimens of DEB025 Alone or in Combination With Ribavirin Versus Standard of Care (Peg-IFNα2a Plus Ribavirin) in Treatment-naïve Hepatitis C Genotype 2 and 3 Patients
- Lead sponsor
- Debiopharm International SA
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2010
- Completion date
- May 31, 2012
- Enrollment
- 340 (actual)
- Sites
- 73
Conditions
As the registry lists them; a condition with its own page is linked.